Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study

˜The œLancet. Gastroenterology & hepatology, Journal Year: 2022, Volume and Issue: 7(6), P. 522 - 532

Published: March 9, 2022

Language: Английский

---

Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes

Cancer Cell, Journal Year: 2019, Volume and Issue: 35(6), P. 932 - 947.e8

Published: May 23, 2019

Language: Английский

---

Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma

Cancer Cell, Journal Year: 2021, Volume and Issue: 40(1), P. 70 - 87.e15

Published: Dec. 30, 2021

Language: Английский

---

Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma

Journal of Hepatology, Journal Year: 2020, Volume and Issue: 73(2), P. 315 - 327

Published: March 12, 2020

Language: Английский

---

Metabolic rearrangements in primary liver cancers: cause and consequences

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2019, Volume and Issue: 16(12), P. 748 - 766

Published: Oct. 30, 2019

Language: Английский

---

Probing the Tumor Suppressor Function of BAP1 in CRISPR-Engineered Human Liver Organoids

Cell stem cell, Journal Year: 2019, Volume and Issue: 24(6), P. 927 - 943.e6

Published: May 23, 2019

Language: Английский

---

Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma

Cell Reports, Journal Year: 2019, Volume and Issue: 27(4), P. 1265 - 1276.e4

Published: April 1, 2019

Biliary tract carcinomas (BTCs) are among the most aggressive malignancies and have a poor prognosis. Here, we successfully established organoid lines derived from intrahepatic cholangiocarcinoma, gallbladder cancer, neuroendocrine carcinoma of ampulla Vater. These organoids BTCs were cultured stably for >1 year closely recapitulated histopathology, gene expression, genetic alterations evident in primary tumors. Gene expression profiling revealed that SOX2 could be potential prognostic biomarker patients with BTC. We screened compound library consisting drugs used clinically their ability to suppress found antifungal amorolfine fenticonazole significantly suppressed growth minimal toxicity normal biliary epithelial cells. Patient-derived may powerful research tool clarification molecular pathogenesis discovery biomarkers therapeutic refractory cancers.

Language: Английский

---

Cholangiocarcinoma

Pathologica, Journal Year: 2021, Volume and Issue: 113(3), P. 158 - 169

Published: June 1, 2021

Liver cancer represents the third leading cause of cancer-related death worldwide. Cholangiocarcinoma (CCA) is second most common type liver after hepatocellular carcinoma, accounting for 10-15% all primary malignancies. Both incidence and mortality CCA have been steadily increasing during last decade. Moreover, CCAs are diagnosed at an advanced stage, when therapeutic options very limited. may arise from any tract biliary system it classified into intrahepatic, perihilar, distal CCA, according to anatomical site origin. This topographical classification also reflects distinct genetic histological features, risk factors, clinical outcomes. review focuses on histopathology its differential diagnoses, diagnostic pitfalls.

Language: Английский

---

Current and emerging therapies for advanced biliary tract cancers

˜The œLancet. Gastroenterology & hepatology, Journal Year: 2021, Volume and Issue: 6(11), P. 956 - 969

Published: Oct. 8, 2021

Language: Английский

---

Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma

Hepatology, Journal Year: 2021, Volume and Issue: 74(3), P. 1429 - 1444

Published: March 25, 2021

Genetic alterations in intrahepatic cholangiocarcinoma (iCCA) are increasingly well characterized, but their impact on outcome and prognosis remains unknown.This bi-institutional study of patients with confirmed iCCA (n = 412) used targeted next-generation sequencing primary tumors to define associations among genetic alterations, clinicopathological variables, outcome. The most common oncogenic were isocitrate dehydrogenase 1 (IDH1; 20%), AT-rich interactive domain-containing protein 1A (20%), tumor P53 (TP53; 17%), cyclin-dependent kinase inhibitor 2A (CDKN2A; 15%), breast cancer 1-associated (15%), FGFR2 polybromo (12%), KRAS (10%). IDH1/2 mutations (mut) mutually exclusive fusions, neither was associated For all patients, TP53 (P < 0.0001), CDKN2A 0.0001) predicted worse overall survival (OS). These high-risk enriched advanced disease adversely impacted across stages, even when controlling for known correlates (multifocal disease, lymph node involvement, bile duct type, periductal infiltration). In resected 209), TP53mut (HR, 1.82; 95% CI, 1.08-3.06; P 0.03) deletions (del; HR, 3.40; 1.95-5.94; 0.001) independently shorter OS, as did clinical variables liver [P 0.001]; regional metastases 0.001]), whereas KRASmut 1.69; 0.97-2.93; 0.06) trended toward statistical significance. presence both or factors represented extremes (median 18.3 vs. 74.2 months; 0.001), alone 38.6 28.8-73.5) 37.0 27.6-not available) intermediate TP53mut, KRASmut, CDKN2Adel similarly unresectable iCCA. features notable limited no benefit resection over chemotherapy.TP53, KRAS, independent prognostic pathologic stage, treatment. Because profiling can be integrated into pretreatment therapeutic decision-making, combining may identify patient subgroups poor irrespective treatment strategy.

Language: Английский

---